A Phase 3 interventional study of Lower dose atropine sulfate eye drops and Low dose atropine sulfate eye drops in Myopia, sponsored by Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 6 Years to 10 Years. Per ClinicalTrials.gov, last updated 2025-07-30.
Sponsored by Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. (formerly part of Lee's Pharmaceutical Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.
Among the 54 studies testing atropine in Myopia, this one is the 5th largest by enrollment, is one of 5 that started in 2022, is one of 13 in phase 3, reaches primary completion later than 0 of the 23 other live ones, and was the 35th registered.
1,162 studies on the registry are indexed under Myopia; 226 are open to participants now.
Browse Myopia studies →17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:
Jaeb Center for Health Research · Sites in United States
Ages 5–11
Ohio State University · Sites in United States
Ages 6–11 · Healthy volunteers
IDB VisionCare SDN BHD · Sites in Malaysia
Ages 5–10
Ocus Innovation Ireland Limited · Sites in Albania, Italy, Poland and 2 more countries
Ages 3–17
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 3–6
By country, each count listing its studies:
Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.
This study: 6 Years to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 16 · Phase 4 8
First in 2005; this study’s year is marked. 5 started in 2022.
This study's enrollment of 526 is above the median of 79 across 924 interventional studies indexed under Myopia.
Median enrollment 144 across the 54 interventional studies. Of the 23 that completed or were terminated, 6 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd., one of the names counted as Lee's Pharmaceutical Limited. Under that name alone:
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. is the lead sponsor of 17 studies on the registry; 4 are open to participants now.
Lee's Pharmaceutical Limited has 0 studies filed under Myopia — fewer than ten, so there is no comparison to draw.
8 of the studies testing atropine in Myopia that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06708156Phase 3Oupushifang Pharmaceutical Technology Co., Ltd.The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression | 2026-12-31 |
| NCT07329777Phase 3IDB VisionCare SDN BHDAtropine in the Treatment of Myopia Study in Malaysia | 2027-09 |
| NCT07164092Phase 3Mansoura UniversityEfficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center | 2027-09 |
| NCT06667037Zhongshan Ophthalmic Center, Sun Yat-sen UniversityOrthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control | 2026-12-31 |
| NCT05379855Eye & ENT Hospital of Fudan UniversityA-eyedrops on Ocular Alignment and Binocular Vision | 2027-02-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 54 studies testing atropine in Myopia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was a randomized, double-blind, placebo-controlled, multicenter, superiority design, phase III clinical trial to compare the efficacy and safety of two low-concentration atropine sulfate eye drops versus placebo in delaying myopia progression in children.
Eligible subjects were screened and randomly assigned to the placebo control group, the lower dose group, and the lower dose group. Subjects received the study drug in both eyes, 1 drop each time, once every night before sleep, for continuous administration.A total of 526 subjects were planned to be enrolled。
Statistical analyses were performed with the use of SAS software, version 9.4, without any specific description. All statistical tests were two-sided at a 0.05 level.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Chronic use of any topical or systemic antimuscarinic/anticholinergic medications (e.g.,atropine, scopolamine, tropicamide) within 21 days prior to screening and/or anticipated need for chronic use during the study period (i.e., more than 7 consecutive days in 1 month or more than 30 total days in 1 year).
Use of cycloplegic drops for dilated ocular exam was allowable.
1 drop each time, once every night at bedtime
Drug: Lower dose atropine sulfate eye drops · Drug: Low dose atropine sulfate eye drops
1 drop each time, once every night at bedtime
Drug: Low dose atropine sulfate eye drops
1 drop each time, once every night at bedtime
Drug: placebo
Administer to eyes
Also known as: Eye drops
Administer to eyes
Also known as: Eye drops
Administer to eyes
Also known as: Eye drops
Cycloplegic Autorefraction(low)
Group difference in the proportion of subjects eyes with myopia progression (SER) less than -0.50 D at M12 visit with low atropine versus placebo.
Time frame: twelve months
Cycloplegic Autorefraction(lower)
Group difference in the proportion of subjects eyes with myopia progression (SER) less than -0.50 D at M12 visit with lower atropine versus placebo.
Time frame: twelve months
Cycloplegic Autorefraction(SER)
Between-group difference in the mean change from baseline in SER at visit M12
Time frame: twelve months
Axial Length
Between-group difference in the mean change from baseline in axial length at visit M12
Time frame: twelve months
Crystalline Lens Thickness
Between-group difference in the mean change from baseline in crystalline lens thickness at visit M12
Time frame: twelve months
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2022 to primary completion in Aug 2023, 15 months.
Of 25 phase 3 interventional studies under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 57. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ophthalmic Solutions · Atropine
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. →